Medicines List

Description

Peximyr contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.

Indications

Peximyr is used to:
– treat the symptoms of primary Parkinson’s disease in adults. It can be used alone or in combination with levodopa (another medicine for Parkinson’s disease);
– treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.

Subject to medical prescription.

Concentration and pharmaceutical form: 0,18 mg; 0,7 mg tablets

Description

PlaquEx contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming.

Indications

Secondary prevention of atherothrombotic events
Clopidogrel is indicated in:
– adult patients suffering from myocardial infarction (from a few days to 35 days), ischaemic stroke (from the 7^th day to the 6^th month) or established peripheral arterial disease;
– adult patients suffering from acute coronary syndrome:
– non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
– ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

Subject to medical prescription.

Concentration and pharmaceutical form: 75 mg film-coated tablets

Description

Spironolacton-Tchaikapharma stimulates the excretion of urine in patients who have fluid accumulation in the tissues (edema) or in the abdominal cavity (ascites) by increasing the amount of sodium (salt) excreted in the urine.

Indications

Spironolacton-Tchaikapharma is indicated for the treatment of:
– congestive cardiac failure;
– hepatic cirrhosis with ascites and oedema;
– malignant ascites;
– nephrotic syndrome;
– diagnosis and treatment of primary aldosteronism (syndrom of Conn);
– hypertension in combination with other antihypertensive products, especially when prone to hypokalaemia.

Subject to medical prescription.

Concentration and pharmaceutical form: 25 mg, 50 mg, 100 mg film-coated tablets